Drug intelligence / Profile preview

cisplatin + rAd-p53 + vinorelbine

Development stage: Preclinical
Lead developer: Michigan State University
Modality: Small Molecules, Gene Therapies
Administration: Intravenous, Intratumoral

Overview

A combination therapy consisting of cisplatin (a platinum-based chemotherapy agent), rAd-p53 (a recombinant adenovirus carrying the p53 tumor suppressor gene), and vinorelbine (a vinca alkaloid chemotherapy agent). This regimen combines conventional chemotherapy with gene therapy approaches for cancer treatment.

Targets

TP53 (Cellular Tumor Antigen p53 R175H)TUBB (Tubulin (alpha and beta subunits))DNA

Beyond the preview

Go deeper on cisplatin + rAd-p53 + vinorelbine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cisplatin + rAd-p53 + vinorelbine.

Explore the full profile